Neurogene Inc. (NGNE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Neurogene reported revenue of $0, down 100.0% from $925,000 the year before. Net income was -$90.4M, or -$4.24 per diluted share. Operating activities generated -$77.2M of cash, leaving -$78.4M of free cash flow. At fiscal year end, Neurogene held $288.6M in total assets against $23.7M in total liabilities, including $103.8M of cash and equivalents.
Open the full interactive Neurogene financials → Quarterly statements, key ratios, valuation history and price charts.
Neurogene Key Stats
| Share Price | $21.56 |
|---|---|
| Market Cap | $486.2M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $16.37 – $42.84 |
| Shares Outstanding | 22.6 million (basic, 2026 Q2) |
Neurogene Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $925,000 | $0 |
| Operating Income | -$33.7M | -$60.7M | -$59.1M | -$55.6M | -$82.6M | -$103.3M |
| Pre-Tax Income | -$33.3M | -$60.7M | -$57.6M | -$36.3M | -$75.1M | -$90.4M |
| Income Tax | — | — | -$21,000 | — | — | $0 |
| Net Income | -$33.3M | -$60.7M | -$57.6M | -$36.3M | -$75.1M | -$90.4M |
| Diluted EPS | -$12.80 | -$22.00 | -$20.80 | — | -$4.28 | -$4.24 |
Neurogene Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$21.0M | -$24.7M | -$30.9M | -$34.5M |
| Diluted EPS | -$0.99 | -$1.16 | -$1.39 | -$1.53 |
Neurogene Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $192.6M | $142.5M | $37.9M | $148.2M | $136.6M | $103.8M |
| Current Assets | $194.5M | $144.0M | $99.1M | $200.3M | $315.9M | $271.8M |
| Total Assets | $210.5M | $163.3M | $115.9M | $222.6M | $335.7M | $288.6M |
| Current Liabilities | $7.9M | $8.6M | $11.1M | $23.0M | $15.2M | $16.4M |
| Total Liabilities | $19.3M | $20.4M | $21.6M | $36.5M | $25.4M | $23.7M |
| Shareholders' Equity | $191.2M | $142.9M | $94.3M | $186.0M | $310.4M | $264.9M |
Neurogene Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$24.6M | -$47.6M | -$45.6M | -$51.4M | -$70.6M | -$77.2M |
| Cash From Investing | -$2.2M | -$3.3M | -$59.1M | $25.6M | -$125.3M | $14.0M |
| Cash From Financing | $77.1M | $732,000 | $161,000 | $92.5M | $184.1M | $30.4M |
| Free Cash Flow | -$26.8M | -$50.8M | -$46.7M | -$51.7M | -$71.4M | -$78.4M |
Figures from Neurogene's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Neurogene financials page for every line item.
Neurogene Company Profile
| Ticker | NGNE |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001404644 |
Frequently Asked Questions
What was Neurogene's revenue in fiscal 2025?
Neurogene (NGNE) reported revenue of $0 for fiscal 2025.
What is Neurogene's annual revenue history?
Neurogene's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $925,000; 2025: $0.
What was Neurogene's net income in fiscal 2025?
Neurogene reported net income of -$90.4M for fiscal 2025.
What was Neurogene's earnings per share (EPS) in fiscal 2025?
Neurogene's diluted EPS was -$4.24 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Neurogene generate in fiscal 2025?
Neurogene generated -$78.4M of free cash flow in fiscal 2025.
What was Neurogene's revenue last quarter?
In its most recent reported quarter (2026 Q2), Neurogene reported revenue of $0.
How many shares of Neurogene are outstanding?
Neurogene reported a weighted average of 22.6 million basic shares outstanding in 2026 Q2.
What is Neurogene's market cap?
Based on its latest closing price, Neurogene (NGNE) has a market capitalization of about $486.2M.
When does Neurogene's fiscal year end?
Neurogene's fiscal year end, as registered with the SEC, is December 31.
Where is Neurogene headquartered?
Neurogene lists its business address in New York, New York in its SEC filings.